MX2022001942A - Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. - Google Patents

Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.

Info

Publication number
MX2022001942A
MX2022001942A MX2022001942A MX2022001942A MX2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A MX 2022001942 A MX2022001942 A MX 2022001942A
Authority
MX
Mexico
Prior art keywords
antigen
binding molecules
multispecific antigen
cell targeting
cell
Prior art date
Application number
MX2022001942A
Other languages
English (en)
Spanish (es)
Inventor
Eric Smith
Lauric Haber
Chia-Yang Lin
Jennifer A Finney
Ryan Mckay
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2022001942A publication Critical patent/MX2022001942A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2022001942A 2019-08-15 2020-08-14 Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas. MX2022001942A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962887411P 2019-08-15 2019-08-15
US201962924435P 2019-10-22 2019-10-22
US202062978584P 2020-02-19 2020-02-19
US202063057824P 2020-07-28 2020-07-28
PCT/US2020/046352 WO2021030680A1 (en) 2019-08-15 2020-08-14 Multispecific antigen-binding molecules for cell targeting and uses thereof

Publications (1)

Publication Number Publication Date
MX2022001942A true MX2022001942A (es) 2022-07-27

Family

ID=72243251

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001942A MX2022001942A (es) 2019-08-15 2020-08-14 Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.

Country Status (12)

Country Link
US (4) US12077603B2 (enExample)
EP (1) EP4013797A1 (enExample)
JP (2) JP7629906B2 (enExample)
KR (1) KR20220044821A (enExample)
CN (2) CN114302893B (enExample)
AU (1) AU2020330063A1 (enExample)
BR (1) BR112022002012A2 (enExample)
CA (1) CA3147791A1 (enExample)
IL (1) IL290299A (enExample)
MX (1) MX2022001942A (enExample)
TW (2) TWI890689B (enExample)
WO (1) WO2021030680A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en) * 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
EP4004049A1 (en) 2019-07-24 2022-06-01 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
AU2022271212A1 (en) * 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
CA3227537A1 (en) * 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
WO2023183758A2 (en) * 2022-03-19 2023-09-28 Regeneron Pharmaceuticals, Inc. Multispecific molecules targeting cd3 and mage-a4 and uses thereof
JP2025525886A (ja) * 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
JP2026507123A (ja) * 2023-02-28 2026-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性化剤およびその使用方法
WO2025199278A2 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked multispecific antigen-binding molecules with cleavable linkers
WO2025255480A1 (en) * 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991003493A1 (en) * 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US7550143B2 (en) * 2005-04-06 2009-06-23 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
CA2604032C (en) * 2005-04-06 2017-08-22 Ibc Pharmaceuticals, Inc. Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
PE20120540A1 (es) * 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
MY192182A (en) 2009-06-26 2022-08-04 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2014124186A (ja) 2012-12-26 2014-07-07 Industrial Technology Research Institute 多価抗体フラグメントおよびその三量体化複合体
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
WO2017106462A1 (en) * 2015-12-18 2017-06-22 Biogen Ma Inc. Bispecific antibody platform
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
JP7066690B2 (ja) 2016-09-23 2022-05-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ｍｕｃ１６（ムチン１６）抗体
WO2018178074A1 (en) * 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor

Also Published As

Publication number Publication date
JP2025072461A (ja) 2025-05-09
CA3147791A1 (en) 2021-02-18
JP7629906B2 (ja) 2025-02-14
US20230068129A1 (en) 2023-03-02
TWI890689B (zh) 2025-07-21
CN114302893B (zh) 2025-01-28
AU2020330063A1 (en) 2022-03-24
US12077603B2 (en) 2024-09-03
US12065508B2 (en) 2024-08-20
US20240368312A1 (en) 2024-11-07
KR20220044821A (ko) 2022-04-11
US20210047438A1 (en) 2021-02-18
US11952430B2 (en) 2024-04-09
TW202542199A (zh) 2025-11-01
JP2022545647A (ja) 2022-10-28
BR112022002012A2 (pt) 2022-06-07
CN119954933A (zh) 2025-05-09
EP4013797A1 (en) 2022-06-22
IL290299A (en) 2022-04-01
TW202120553A (zh) 2021-06-01
WO2021030680A1 (en) 2021-02-18
US20220251244A1 (en) 2022-08-11
CN114302893A (zh) 2022-04-08

Similar Documents

Publication Publication Date Title
MX2022001942A (es) Moléculas de union a antígeno multiespecíficas para el direcciónamiento célular y usos de las mismas.
WO2021097365A3 (en) Antigen-binding proteins targeting shared neoantigens
AU2018318303A1 (en) Antigen-binding proteins targeting shared antigens
WO2019241430A3 (en) Antibody-oligonucleotide conjugates
GEP20257822B (en) Mcl-1 inhibitor antibody-drug conjugates and methods of use
MY205343A (en) Anti-muc1 antibody
PH12016501384B1 (en) Human antibodies to pd-l1
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
MX2025002735A (es) Virus oncolitico que codifica un inhibidor de la molecula 4 asociada a linfocitos t citotoxicos (ctla-4) y su uso en el tratamiento de cancer
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
MX2015014608A (es) Novedosas moleculas de union biespecifica con actividad antitumoral.
EP4556020A3 (en) Antibody molecules
SA520420582B1 (ar) Cd3 أجسام مضادة خاصة لـ واستخداماتها
MY209796A (en) Fusion protein constructs for complement associated disease
PH12018502293B1 (en) Humanized anti-basigin antibodies and the use thereof
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
WO2018071822A8 (en) ANTIBODIES BINDING TO THE ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
MY204733A (en) Anti-pd-l1 antibodies and use thereof
ZA202205288B (en) Humanized antibody and method for using the same
ECSP21028958A (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
WO2015191590A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2021041300A3 (en) Bispecific antibodies and uses thereof
MX2022007116A (es) Anticuerpo anti-c5 para el tratamiento del trastorno del espectro de la neuromielitis optica.
MX2022003191A (es) Terapias de combinacion con anticuerpos entpd2 y cd73.
WO2015191583A3 (en) Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase